Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 3/20 | 1.00 |
| ▸ | ALB | P02768 | 3/20 | 0.64 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.41 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.38 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Emtricitabine 5'-Triphosphate SCHEMBL606449 | 1.00 | POLG (1.00) | POLGALBCACNA1FLMNAMAPT | |
| Emtricitabine 5'-Triphosphate SCHEMBL14354587 | 1.00 | POLG (1.00) | POLGALBCACNA1FLMNAMAPT | |
| SCHEMBL4373149 | 0.90 | POLG (0.82) | POLGALBCACNA1FLMNAMAPT | |
| SCHEMBL13199313 | 0.83 | POLG (0.71) | POLGALBP2RY2P2RY4P2RY6 | |
| SCHEMBL6909903 | 0.83 | POLG (0.71) | POLGALBP2RY2P2RY4P2RY6 | |
| Lamivudine Triphosphate SCHEMBL14354589 | 0.83 | POLG (1.00) | POLGALBCACNA1FLMNAMAPT | |
| Lamivudine Triphosphate SCHEMBL2223243 | 0.83 | POLG (1.00) | POLGALBCACNA1FLMNAMAPT | |
| Lamivudine Triphosphate SCHEMBL12595501 | 0.83 | POLG (1.00) | POLGALBCACNA1FLMNAMAPT | |
| SCHEMBL25492503 | 0.82 | POLG (0.70) | POLGP2RY2P2RY4P2RY6 | |
| SCHEMBL8409011 | 0.82 | POLG (0.70) | POLGP2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250237642-A1 | PREDICTIVE MODEL FOR VARIANTS ASSOCIATED WITH DRUG RESISTANCE AND THERANOSTIC APPLICATIONS THEREOF | UNIV EMORY (US) | 2025-07-24 | — | — | US | disclosed |
| WO-2023172635-A1 | PREDICTIVE MODEL FOR VARIANTS ASSOCIATED WITH DRUG RESISTANCE AND THERANOSTIC APPLICATIONS THEREOF | EMORY UNIVERSITY (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230172961-A1 | THERAPEUTICS FOR COVID-19 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172961-A1 | THERAPEUTICS FOR COVID-19 | ACE, ACE2, PNP | POLG 147/4885ALB 3707/4885CACNA1F 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.